Jódar E, Romera I, Wang Q, et al. - Dulaglutide use as a monotherapy or added to oral glucose-lowering medication, without concomitant insulin treatment, was found to be potentially related to a reduction in glycemic variability (GV) in type 2 diabetes mellitus (T2D) patients.

• By conducting post hoc analyses of six randomized, Phase 3 studies, the link between treatment with dulaglutide 1.5 mg once weekly and GV was examined in adult patients with T2D.

• Data were pooled from five studies with dulaglutide as a monotherapy or added to oral glucose-lowering medication, without concomitant insulin treatment.

• Results revealed that the dulaglutide group exhibited clinically meaningful decreases in within- and between-day self-monitored plasma glucose (SMPG), and between-day fasting glucose from SMPG variability from baseline.

• A greater degree of GV reduction was evident with dulaglutide vs insulin glargine.

• When added to insulin glargine, dulaglutide use was found to be linked with greater reductions in GV than insulin glargine alone.

• Decreased GV may be related to better outcomes.